MedImmune gets Fast Track nod

AstraZeneca subsidiary MedImmune scored the FDA's fast track designation for its experimental treatment to prevent nosocomial pneumonia, which is caused by a highly drug-resistant pathogen. The drugmaker says the Phase-I monoclonal antibody has three distinct mechanisms of action to disarm and clear the bacterium. AstraZeneca says it is also exploring the drug as a preventative measure.